I think almost all CEOs, especially those of OTC, know one way to increase pps value is to deluge shareholders and potential buyers with PR after PR. The problem I've seen with that is the pps will quickly tank when they slow down or when shareholders catch on if there's nothing real (or something anticipated falls apart)... in my mind, the pps should rise and fall based on the bottom line of a company and real potential.... that the company is even real with a real product(s) and/or service(s)... and the potential to SHOW REVENUE, if not outright show it.
And startups in particular ... especially biotech ones... take years before they get off the ground as we've seen and are seeing with cydy and GNBT. They MUST have something real that is in demand... and eventually show revenue. Both of these have seen reaction just because of the unfortunate Covid-19... albeit GNBT has yet to really respond better.
I do agree with our CEO here, one has to stand by their 'investment' and support a company if they believe, otherwise don't bother putting your hard-earned dollars into it and just move on....
Generex Biotechnology Corp. (GNBT) Stock Research Links